Peer-reviewed veterinary case report
Dog vaccine CaniLeish protects against leishmaniasis for one year
By Martin, Virginie et al.·Published in Veterinary research·2014·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.
- Species:
- dog
Plain-English summary
A group of dogs was vaccinated with the LiESP/QA-21 vaccine to protect against leishmaniasis, a disease caused by a parasite. One year later, these dogs were exposed to the parasite to see if the vaccine still worked. The vaccinated dogs showed strong immune responses and had much lower levels of the parasite compared to unvaccinated dogs. This suggests that the vaccine remains effective for at least a year, helping to prevent serious infections in dogs at risk of leishmaniasis.
People also search for: dog leishmaniasis vaccine effectiveness · LiESP QA-21 vaccine for dogs · how long does leishmaniasis vaccine last
Abstract
Control of canine leishmaniasis is an important objective for the benefit of dogs living in or visiting endemic areas and for public health because of the zoonotic nature of this disease. Resistance or susceptibility to developing canine leishmaniasis after exposure to Leishmania infantum is primarily determined by the ability of the immune system to develop an appropriate Th1-dominated specific response to the parasite. For this reason there is a need for effective canine vaccines that can decrease the number of dogs developing progressive infections. In this study, we followed the impact of the LiESP/QA-21 canine vaccine (composed of excreted-secreted proteins of L. infantum and the QA-21 saponin adjuvant), recently launched commercially in Europe, on selected humoral and cellular immune parameters following an infectious intravenous challenge with L. infantum promastigotes administered one year after the primary vaccine course. We also followed parasitological parameters to determine the parasitological status of the challenged dogs. In contrast to controls, vaccinated dogs retained significantly stronger cell-mediated immune responses against the parasite despite a virulent challenge and had significantly lower mean parasite burdens at the end of the study, associated with a lower probability of developing active infections. These results confirm that the immune responses generated by vaccination with LiESP/QA-21 are still effective against an intravenous challenge one year after the primary vaccine course.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24964736/